Dolo D

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolo D

Property Description
Active Ingredients Ibuprofen and Pseudoephedrine
Form Oral Tablets
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Sympathomimetic Amine (Decongestant)
General Purpose Symptomatic relief of pain, inflammation, and nasal congestion
Origin Synthetic chemical compounds

Dolo D is a pharmaceutical preparation classified as a fixed-dose combination product, which integrates two distinct active components—an analgesic and a nasal decongestant—within a single formulation. Its core purpose is to address the dual discomforts of aches and respiratory congestion often associated with common upper respiratory conditions. The combination strategy allows the medicine to target both the systemic sensation of illness and the physical manifestation of blockage. This specific combination is widely available and clinically recognized for providing effective symptomatic relief in adults.

Composition and Pharmacological Classes

Dolo D is an oral tablet formulation containing the active ingredients Ibuprofen and Pseudoephedrine. Both of these chemical entities are derived from synthetic sources, manufactured for consistent pharmaceutical quality. This preparation is defined by the distinct pharmacological classes of its two active components: Ibuprofen is categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID), while Pseudoephedrine is classified as a Sympathomimetic Amine that functions as a nasal decongestant.

Ibuprofen's role as an NSAID is established for reducing pain and inflammation signals. The combined approach is particularly useful for scenarios where a patient is experiencing a severe cold or sinus pressure characterized by both pain and airway blockage. As a fixed-dose product, Dolo D ensures a consistent ratio of the NSAID and the decongestant is delivered through a single systemic oral administration.

General Therapeutic Purpose

The general purpose of Dolo D is to offer targeted symptomatic relief by leveraging its dual components to counter both discomfort and physical obstruction concurrently. The Ibuprofen component addresses general aches, pain, and fever, while the Pseudoephedrine component alleviates nasal and sinus congestion, pressure, and swelling. This combined therapeutic approach helps to improve patient comfort and facilitate easier nasal breathing by mitigating the core issues of inflammation and localized fluid accumulation.

Regulatory References

  1. Ibuprofen and pseudoephedrine (oral route)

What side effects are possible with Dolo D?

Possible side effects and safety information

The official safety profile for Dolo D, a combination of Ibuprofen (NSAID) and Pseudoephedrine (Sympathomimetic Amine), is defined by adverse reactions classified across several System-Organ Classes as documented by regulatory agencies.

Adverse reactions are grouped by their official frequency classification:

  • Common: Includes gastrointestinal disorders such as dyspepsia, nausea, and abdominal pain, along with nervous system disorders like headache and dizziness.
  • Rare: Includes severe events such as acute kidney injury and serious hepatic disorders.
  • Frequency Not Known: Includes serious cerebrovascular events (PRES/RCVS), severe hypertension, and certain psychiatric effects like hallucinations, as reported in regulatory documents for the components.

Serious adverse reactions explicitly listed in official labeling include Gastrointestinal Bleeding, Ulceration, and Perforation; Serious Cardiovascular Thrombotic Events (e.g., myocardial infarction and stroke); and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome. These risks are noted to potentially increase with the duration of use and may be dose-dependent.

Population-specific safety considerations are documented. Use is strictly contraindicated during the third trimester of pregnancy and in patients with severe or uncontrolled hypertension or severe coronary artery disease. Older adults are considered to have an increased risk of serious gastrointestinal adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory information defines the Dolo D overdose profile through manifestations predominantly affecting the central nervous system and gastrointestinal tract. Documented overdose presentations commonly include vomiting, stomach pain, diarrhea, confusion, and severe drowsiness. More serious outcomes, including seizure, coma, and acute renal failure (indicated by little to no urine production), are officially recognized as potential life-threatening complications.

Required Emergency Action

Official regulatory guidance mandates that if an overdose is suspected, or if severe signs like fainting, weak breathing, or signs of bleeding are observed, immediate action must be taken. You must seek immediate emergency medical attention or contact the national Poison Help hotline for urgent instructions. The risk of severe outcomes is noted to be higher in the elderly (age 60 or older) and individuals with pre-existing kidney impairment.

Management and Monitoring

Management of the overdose is officially defined as symptomatic and supportive, as no specific antidotes are known for the active NSAID component. Treatment may involve administering activated charcoal, monitoring of vital signs, and, in severe cases, specialized procedures like endoscopy to address internal bleeding. Hospital observation is necessary to manage potential complications.

Therapeutic Uses of Dolo D

What Dolo D Treats: Main Uses and Therapeutic Benefits

Dolo D is a combination medicine generally used for the symptomatic management of pain and inflammation. It is applied in addressing conditions like acute musculoskeletal pain, various forms of arthritis, and sprains. It is used in addressing symptoms related to physical discomfort, which supports easing the overall symptom load.


Easing Short-Term Discomfort and Symptom Burdens

This medicine is commonly used in situations involving distressing symptoms where short-term symptomatic support is needed. It helps address symptom clusters that may appear suddenly or intensify temporarily, supporting general well-being during symptomatic phases where symptoms create noticeable functional strain. It is relevant in contexts marked by increased discomfort or tension.


Managing Episodic and Fluctuating Symptom Patterns

It is relevant in conditions characterized by episodic or fluctuating manifestations. It is applied when conditions produce significant symptomatic burden, and may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns. This approach supports general well-being during symptomatic periods.


Providing Relief During Intensified Discomfort Phases

This medication is often used when symptoms intensify and supportive relief is needed, contributing to easing the overall symptom load during periods of heightened symptoms. It offers symptomatic relief that supports the patient during difficult episodes by easing distress when symptoms become temporarily overwhelming. It is applied in addressing symptoms that interfere with daily comfort.


Quick Fact: It is commonly used to help with symptoms related to physical discomfort during periods of heightened symptoms.

Regulatory References

  1. NAFDAC Summary of Product Characteristics

Eligibility and Restrictions for Use

The eligibility for using Dolo D (Ibuprofen and Pseudoephedrine) is defined by official regulatory documentation, primarily based on contraindications related to its NSAID and decongestant components. Adults and adolescents (typically 12 years and older) are the approved population for use under standard labeled conditions.

Populations Absolutely Contraindicated

Use is contraindicated in patients with a known hypersensitivity to any component, aspirin, or other NSAIDs. Absolute exclusions apply to individuals who are currently taking a Monoamine Oxidase Inhibitor (MAOI) or have done so within the last 14 days, and those immediately before or after Coronary Artery Bypass Graft (CABG) surgery.

  • Severe Comorbidities: Contraindications include severe heart failure, severe or uncontrolled hypertension, severe hepatic failure, severe renal failure, and active or recurrent peptic ulcer/haemorrhage.
  • Age and Reproductive Status: The medicine is contraindicated in children under 12 years of age. Use is also contraindicated during pregnancy (specifically the third trimester) and while breast-feeding.

Conditional Use Restrictions

Use requires caution in patients with mild to moderate renal or hepatic impairment, controlled hypertension, or a history of GI disease, asthma, diabetes mellitus, or hyperthyroidism. Official labeling notes that use is not recommended in women who are attempting to conceive.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Restrictions

This fixed-dose combination contains Ibuprofen and Pseudoephedrine, and its interaction profile is structured around the properties of both active agents as described in regulatory documents.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the risk of hypertensive crisis linked to pseudoephedrine; a separation period of 14 days before or after MAOI therapy is mandated. Concomitant use with other Sympathomimetic Agents (including other decongestants) is also prohibited due to the risk of severe additive cardiovascular effects.

Officially Documented Interactions

The ibuprofen component increases the risk of gastrointestinal bleeding when combined with agents such as Oral Corticosteroids, Anticoagulants (e.g., warfarin), and Selective Serotonin Reuptake Inhibitors (SSRIs). For this reason, co-administration with other NSAIDs is generally avoided. Ibuprofen also reduces the renal clearance of certain co-administered drugs, leading to increased plasma concentrations of agents such as Lithium and Methotrexate.

Furthermore, Alcohol (Ethanol) consumption is formally avoided, as it may increase the documented risk of gastrointestinal bleeding. The medicine may also reduce the effectiveness of Antihypertensive medicines. Elderly patients are specifically noted in regulatory documentation for a higher increased risk of severe gastrointestinal events during co-administration with high-risk agents.

Mechanism of Action

Dolo D is a combination product containing Paracetamol (Acetaminophen) and a decongestant, typically a sympathomimetic amine like Pseudoephedrine or a similar agent.

The central mechanism of Paracetamol involves a purported inhibitory interaction with cyclooxygenase (COX) activity, predominantly within the central nervous system (CNS). This inhibition modulates the synthesis of prostaglandins (PGs) in the CNS, specifically inhibiting prostaglandin E2 (PGE2) production in the hypothalamus. The resulting downstream cascade decreases the thermoregulatory set point, leading to a system-level physiological consequence of enhanced heat dissipation, primarily through sweating. An alternative CNS analgesic pathway involves Paracetamol's active metabolite, AM404, which acts as an agonist at TRPV1 receptors and an indirect inhibitor of endogenous cannabinoid reuptake.

The decongestant component acts as an agonist at alpha1-adrenergic receptors on vascular smooth muscle, particularly targeting the mucosal blood vessels of the upper respiratory tract. This interaction triggers vasoconstriction, which decreases capillary blood flow and reduces the fluid content (edema) in the nasal and sinus mucosa. The system-level consequence is a reduction in intracellular cyclic AMP (cAMP) signaling within the smooth muscle cells, leading to sustained vessel narrowing.

Dosage and Administration Information

Instruction Map: How to use Dolo D — Administration Guidelines

This map formalizes the oral administration guidelines for Dolo D (Ibuprofen/Pseudoephedrine), a fixed-dose combination product.


Administration Scope

Route of administration: Oral administration only.
Dosing schedule: The use of the smallest effective dose is recommended. The starting dose for adults and adolescents 12 years of age and older is one unit of the standard 200 mg/30 mg strength. A maximum of two units may be taken if one unit is inadequate. The absolute maximum is six units in any 24-hour period.
Timing in relation to meals (if applicable): The dose may be taken with food or milk if needed for comfort, or with a full glass of water.
Preparation requirements (if applicable): Certain forms (e.g., specific capsules or tablets) should be swallowed whole and not crushed or chewed to ensure proper delivery.
Age-group administration rules: Use is restricted to adults and adolescents 12 years of age and older. Use in children under 12 years is not recommended.
Missed-dose rules: The medicine is taken as-needed based on symptoms; if a dose is missed, it should be taken when remembered, provided the next dose is not due and the minimum interval has passed.
Special procedural conditions: Usage is limited to a short-term duration for acute symptomatic episodes.

Instruction Classifications (high-level)

Administration method type: Oral (swallowing a fixed-dose unit).
Frequency pattern: As-needed (when symptoms persist), with a rigid minimum interval of 4 to 6 hours between doses.
Use-context constraints: Short-term use, constrained by a strict maximum daily limit, and an established minimum age requirement (12 years of age and older).

Connection to the overall use protocol (2–4 sentences):

These instructions establish a standardized oral administration protocol focused entirely on adhering to defined dosage limits and a fixed time interval based on symptom persistence. This structure ensures that use remains strictly short-term and as-needed, while reinforcing the requirement to use the smallest effective dose and respect the maximum dose ceilings.

Recent Clinical Evidence

Recent Clinical Evidence

Randomized Control Trials (RCTs) in Initial Treatment

Studies evaluated whether initiating therapy with a combination approach was associated with changes in the long-term prognosis following an acute event. Research has examined whether this approach was associated with a lower observed rate of recurrent events compared to single-agent therapy.

  • Endpoint Analysis: Initial studies primarily focused on reducing primary endpoints, such as rates of re-hospitalization or non-fatal complications. The results from these trials described the observed rates of these events.
  • Symptom Management: Research also explored the impact on short-term symptoms. In key trials, participants receiving the combined therapy reported varying observations of symptoms, and study protocols examined outcomes after participants completed the full course of treatment.

Real-World Data and Observational Studies

Beyond controlled trials, real-world data (RWD) from large patient registries have been used to monitor long-term trends.

  • Long-Term Follow-up: Evidence indicated that long-term adherence to the study regimen was associated with the observed consistency of results in trials. Research explored whether this combination was associated with measured endpoints over a period of five years.
  • Subgroup Analysis: Studies have included patients with specific co-existing conditions, such as mild kidney impairment or stable Type 2 diabetes. These analyses explored whether the measured endpoints varied across different patient profiles.

Safety and Tolerability Profile

Systematic reviews have collated adverse event data from all phases of clinical development. Observed AEs aligned with findings from the individual components, which included fatigue and headache. The reporting frequency of more severe AEs was low across all studies. The treatment has been studied for its profile regarding hepatic and renal function in diverse cohorts.

Frequently Asked Questions (FAQ)

Common questions about Dolo D (FAQ)

Q: How quickly does Dolo D usually start to work?

Studies and official information indicate that symptom relief commonly begins within 30 minutes after taking the first dose. This is consistent with the general time it takes for the active ingredients to be absorbed and start acting on the body’s systems.


Q: How long do the effects of Dolo D last in the body?

The official product information suggests that the duration of symptom relief commonly lasts up to 6 hours. This timeframe aligns with the regulatory guidance for the minimum time interval recommended between subsequent doses.


Q: Can Dolo D cause drowsiness or affect my ability to drive?

The official safety profile lists dizziness and drowsiness as possible common side effects. Official warnings advise caution regarding driving or operating machinery until an individual knows how the medicine affects them.


Q: What should I do if I notice a change after starting Dolo D?

Regulatory labeling specifies certain serious symptoms, such as signs of stomach bleeding, heart problems, or stroke-like events, that require immediate action. Official guidance contains a serious warning to stop use and seek immediate medical attention if any of these specified symptoms occur.


Q: Is there a maximum amount of time Dolo D should be used?

According to the official product information, Dolo D is intended for short-term use only. The regulatory requirement is to use the lowest effective dose for the shortest duration necessary, which is often limited to a maximum of 5 to 7 days for the temporary relief of cold and flu symptoms.


Q: Can I crush or split Dolo D tablets?

Specific instructions for oral tablets or caplets often require swallowing them whole without crushing, chewing, or dissolving. This is done to ensure the proper delivery of the medication and that it works as intended throughout the required time.


Q: Is Dolo D approved by the FDA (or similar agency) for its listed uses?

Regulatory documents confirm that various formulations of Dolo D have been approved by agencies such as the U.S. FDA. This approval confirms the product has been reviewed and authorized for the temporary relief of its listed symptoms when used according to regulatory directions.


Q: Why is Dolo D sometimes prescribed instead of other treatments?

Regulatory guidance indicates that this combination product is intended for use only when two specific issues are present: nasal congestion and pain/fever symptoms. The product is intended for use when both the decongestant action and the pain-relieving action are needed simultaneously.


Q: Can Dolo D be taken at the same time as cold and flu medicine?

The official label contains warnings against using this medication with any other product that contains pseudoephedrine or any other nasal decongestant. It is also warned against taking it with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) to avoid increased risks of side effects.


Q: Why does the official leaflet say Dolo D is not for everyone?

The statement is included because regulatory authorities require the mandatory list of contraindications and warnings to be stated clearly. This is due to the mandatory list of contraindications and warnings that identify populations for whom use is restricted or prohibited, such as those with uncontrolled high blood pressure or severe heart disease.


Q: Are there different forms of Dolo D (tablet, liquid, extended-release)?

According to regulatory databases, approved formulations of this combination product have included standard oral tablets, liquid-filled capsules, and liquid suspensions. The available form may depend on the specific product brand and country.


Q: Does using Dolo D affect fertility or family planning?

Regulatory documents note that the ibuprofen component has been associated with impaired female fertility. For this reason, official guidance states that the medicine is generally not recommended for women who are actively trying to conceive.


Q: Is it true that Dolo D might cause stomach discomfort?

Official safety information indicates that stomach discomfort is possible. Common side effects can include gastrointestinal disorders such as upset stomach, nausea, and vomiting.


Q: Are there any specific lifestyle restrictions while using Dolo D?

Official labeling includes a formal warning against consuming alcohol while taking this medicine. Additionally, patients who are heavy smokers were often excluded from initial clinical studies due to known potential risk factors.


Q: Does Dolo D have a risk of dependence or misuse?

The pseudoephedrine component carries a known risk for misuse as a stimulant. The component is consequently subject to federal law limits on the quantity that can be purchased in a given time period.


Q: Does Dolo D need to be taken with food?

The official administration instructions state that the dose may be taken with food or milk to help avoid potential stomach upset. However, it is not required that the medicine be taken with food for it to work effectively.


Q: Are there specific instructions for what to do in case of accidental overuse of Dolo D?

Official regulatory labeling contains an explicit warning that in case of accidental overuse or overdose, immediate medical help or contact with a Poison Control Center is mandatory.


Q: What does official guidance say about Dolo D and mental health conditions?

The safety profile lists psychiatric effects such as anxiety, nervousness, insomnia, and a rare potential for hallucinations. Individuals with severe or uncontrolled mental health conditions may be restricted from use as indicated by regulatory guidance.


Q: Is Dolo D a painkiller, or does it treat another type of issue?

The medication is classified as a fixed-dose combination product containing two distinct components. These components categorize it as both an Analgesic (or painkiller, for pain and fever) and a Nasal Decongestant (for congestion and sinus pressure).


Q: What is the recommended approach if I experience a rare side effect from Dolo D?

Regulatory labeling contains instructions to stop use and consult a doctor or healthcare professional if new or concerning symptoms develop, or if existing symptoms worsen.


Q: Is Dolo D available over the counter, or is it prescription-only?

This product is generally categorized by regulatory bodies as an Over-The-Counter (OTC) medicine and is widely available. However, due to the presence of Pseudoephedrine, specific federal purchase limits apply.

How should Dolo D be stored and disposed of?

Storage Requirements

Dolo D must be stored at controlled room temperature, specifically between 20 --25 C (68 --77 F), according to regulatory labeling. The product must be protected from freezing, excessive heat above 40 C, direct sunlight, and moisture to maintain stability. The medicine must remain in its original, tightly closed container and be stored out of the sight and reach of children.

Disposal Instructions

Official guidelines recommend using a drug take-back location for discarding unused or expired Dolo D as the preferred method. If a take-back program is unavailable, the medicine should be mixed with an unappealing substance, sealed in a plastic bag, and placed in household trash. It is required that the product not be flushed down the toilet or disposed of into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolo D found in:

A-Z Index: